Introduction
Significant progress has been made in the development of prognostic factors for chronic lymphocytic leukemia (CLL), which is difficult to predict using clinical parameters, as some patients exhibit indolent disease for decades while others suffer from rapid progression of the disease and require early treatment (1) . Furthermore, the development of CLL is associated with immune suppression in the host, which contributes to the failure to mount an effective immune response against the cancer cells (2); however, no prognostic factors for indicating the host immune status of CLL patients exist at present.
Myeloid-derived suppressor cells (MDSCs), a subset of T cells, are a heterogeneous population of immature myeloid cells with immunosuppressive function. Therefore, the presence of MDSCs in the tumor microenvironment has been widely investigated (3) . Previously, a novel population of MDSCs, termed cluster of differentiation 14 (CD14) + human leukocyte antigen (HLA)-DR low/-MDSCs, were identified in melanoma, hepatocarcinoma and B-cell non-Hodgkin lymphoma patients (4-6), indicating that low or lacking HLA-DR expression is associated with a CD14 + cell subset, which is highly suppressive of lymphocyte function.
Therefore, the present study analyzed CD14 +
HLA-DR low/-
MDSCs from 49 CLL patients, monoclonal B-cell lymphocytosis (MBL) patients and healthy volunteers. Furthermore, the correlation between CLL patient survival and CD14
+ HLA-DR low/-expression was also investigated. + CD5 + lymphocytes. Additionally, the expression the signal transduction molecule ZAP-70 was provided as the percentage of mean fluorescence intensity (MFI) of the gated events, and regarded as high when >20%. The expression of CD38 was also provided as a percentage of the MFI of the gated events, and was regarded as high when >30%.
Patients and methods

Patients
Immunoglobulin heavy chain (IGHV) gene mutation. The IGHV gene mutation status of the CD19
+ CD5 + cells of all patients was assessed as previously described (9) . Briefly, IgVH gene mutations were detected by polymerase chain reaction and specific primers (cat. no. 5-101-0010), using the IGH Somatic Hypermutation Assay for Gel Detection kit (Invivoscribe Technologies, Inc., San Diego, CA, USA), according to the manufacturer's instructions. Sequences exhibiting <98% homology with the corresponding germline IGHV genes were considered to be mutated.
Statistical analysis. Statistical analysis was performed using GraphPad Prism software (version 5.01; GraphPad Software, Inc., La Jolla, CA, USA) and the following statistical tests were performed: The log-rank test, the Mann Whitney U test and Spearman's rank correlation. In addition, quantitative data are presented as the mean ± standard deviation. 
Results
Correlation between CD14
+ HLA-DR low/-MDSC upregulation and CLL tumor progression. Analysis of the frequency of CD14 + HLA-DR low/-MDSC cells in 49 CLL, 23 MBL and 21 control cases revealed that the frequency of CD14 + HLA-DR low/-cells was significantly elevated in CLL patients compared with MBL and control cases (Fig. 1A and B) , where MBL is a condition that resembles CLL but does not meet all of the criteria for CLL (10) . The clinicopathological data of the studied patients and control cases, including the number of subjects, median age, gender, Rai stage, IGHV mutation status, CD38 status and ZAP-70 status, were recorded (Table I) . Furthermore, statistical analyses revealed that CD14
+ HLA-DR low/-cells were significantly associated with the clinical stage of disease in CLL patients (Fig. 1C) , Table II . Lymphocyte subsets in the CLL, MBL and control groups. P<0.0001), and was significantly higher in the ZAP-70 high subgroup compared with ZAP-70 low subgroup (P=0.0003) (Fig. 2C) . Following data analysis based on the mutational status of IGHV, a similar frequency pattern was observed: The frequency of CD14 + HLA-DR low/-MDSCs was significantly higher in the IGHV-unmutated (U-CLL) and IGHV-mutated (M-CLL) CLL patients when compared with the control (both P<0.0001), and these MDSCs were significantly more elevated in the U-CLL patients compared with the M-CLL patients (P=0.0019) (Fig. 2D) . Furthermore, when patients were divided based on combinations of good (M-CLL/CD38 high subgroup was higher than in the M-CLL/CD38 low subgroup (P=0.0052) (Fig. 2E) . In the present study, it was identified that CD14 (3) . In the present study, the frequency of various lymphocyte subsets were assessed, and it was identified that the frequency of CD3 + T, CD4 + T, CD8 + T and NK cells in CLL patients were significantly reduced compared with in the MBL patients and the control group (Table II) . By contrast, B, T reg and CD19 + CD5 + cells were significantly elevated in CLL patients compared with MBL patients and the control group (Table II) . Furthermore, Spearman's correlation analysis revealed that CD14 + HLA-DR low/-MDSCs were significantly positively correlated with CD19 + CD5 + cells (Fig. 3A ) and negatively correlated with the CD4 + T cells (Fig. 3B) ; however, no significant correlation was identified with CD3 + T, B, T reg or NK cells (data not shown). Data obtained in the present study was inconsistent with previous reports, which described MDSCs as potent inducers of T reg cells in liver cancer patients (4). However, in general, CD14 + HLA-DR low/-MDSCs appear to disturb systemic immunity during CLL disease progression, predominantly by inhibiting the CD4 + T-cell response. Additionally, no correlation was identified between CD14 + HLA-DR low/-MDSCs, and age, serum hemoglobin concentration, platelet and white blood cell count, Rai stage and lymphocytosis (data not shown).
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Discussion
Currently, the use of clinical, biological and genetic parameters allows CLL patients to be diagnosed and characterized with a mild, intermediate or aggressive onset and prognosis of this heterogeneous disease (13) . However, excepting allogeneic stem cell transplantation, there is no curative treatment available for CLL patients, possibly due to CLL patients exhibiting a defective immune antitumor response. Furthermore, in individuals with established CLL, MDSCs are likely to be a major factor in reducing the efficacy of therapeutic treatment strategies, which require an immunocompetent host (14) . Therefore, improved understanding of the immune status of individual CLL patients may be useful for determining which patients may exhibit indolent disease for a number of decades, and which patients may progress rapidly and require early treatment. In addition, the elimination of MDSCs is a priority for CLL patients who are candidates for active immunotherapy.
Presently, there is a requirement to monitor the number of immunosuppressive CD14 + HLA-DR low/-MDSCs (>40% CD14 + monocytes) in CLL patients, as the survival time from diagnosis is currently <3 years. However, additional multivariate statistical analysis with other prognostic factors in long-term multicenter studies should initially be performed to clarify the observations of the current study, as the follow-up period of CLL patients in the present study was only conducted for ~4 years. Furthermore, the specific immunosuppressive function of CD14 + HLA-DR low/-MDSCs in CLL patients requires further investigation.
In conclusion, to the best of our knowledge, the present study reports for the first time a population of immunosuppressive monocytes, characterized by the CD14 + HLA-DR low/-phenotype, which were significantly elevated in CLL patients and were poor predictors of survival in CLL patients (n=49). In addition, these CD14 + HLA-DR low/-MDSCs were associated with the prognostic factors CD38, ZAP-70 and IGHV. 
